Abbott Ventures
Abbott Laboratories is a diversified global healthcare company that develops medical devices, diagnostics, nutrition, and pharmaceuticals across cardiovascular, diabetes, oncology, and consumer health. It serves hospitals, providers, and consumers in more than 35 countries.
- Company typePublic
- Founded1888
- HeadquartersCarthage, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
Abbott Ventures firmographics
Firmographics- Name
- Abbott Ventures
- Legal name
- Abbott Laboratories
- Website
- https://abbott.com
- Company type
- Public
- Founded year
- 1888
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Abbott Laboratories is a diversified global healthcare company that develops medical devices, diagnostics, nutrition, and pharmaceuticals across cardiovascular, diabetes, oncology, and consumer health. It serves hospitals, providers, and consumers in more than 35 countries.
- Ownership category
- akta.pro rank
Abbott Ventures industry classification
Industry- Product category
- Venture Capital Investment
- NAICS
- All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Abbott Ventures is headquartered
LocationHeadquarters
- HQ city
- Carthage
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Abbott Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Revenue model
- Medical Devices: Cardiovascular devices including heart valves, LVADs, pacemakers, implantable cardiac monitors, and structural heart devices. This segment performed well in Q3 2025 with sales surpassing forecasts, offsetting weakness in other segments.
- Diagnostics: Diagnostic testing products including COVID-19 testing which has seen declining demand. Weakness in diagnostics impacted overall performance in Q3 2025.
- Nutrition: Nutritional products including Ensure, Similac, Pedialyte, and Pedialyte Sport. This segment experienced weakness alongside diagnostics in Q3 2025.
- Established Pharmaceuticals: Branded and generic pharmaceutical products across multiple markets.
- Cancer Testing (via Exact Sciences): Following the acquisition of Exact Sciences, Abbott now offers Cologuard, Cologuard Plus, Cancerguard, Oncotype DX, and Oncodetect cancer screening and diagnostic tests.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Pedialyte Sport - Electrolyte drink with 3x electrolytes and 1/4 the sugar of leading sports drinks |
| Unit Pricing | Pay-as-you-go | Ensure Max Protein nutrition shakes |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels9 records
Abbott Ventures product offering
Product offeringCore offering
Abbott Ventures is a corporate venture capital subsidiary of Abbott that makes equity investments in emerging medical technology companies. It deploys strategic capital into early- and growth-stage medtech businesses, leveraging the parent organization's healthcare industry presence and product portfolio spanning medical devices, diagnostics, nutrition, and pharmaceuticals.
Product overview
Abbott is a global healthcare company offering a diversified portfolio of medical devices, diagnostics, nutrition products, and pharmaceutical products organized across several business segments. The core product portfolio includes FreeStyle Libre continuous glucose monitoring systems for diabetes care, cardiovascular devices including HeartMate 3 LVAD, Amplatzer occluders, CardioMEMS HF system, AVEIR DR pacemaker, Masters Series mechanical heart valves, and TriClip G4 system for structural heart repair. Following the 2025 acquisition of Exact Sciences, Abbott expanded into cancer diagnostics with Cologuard, Oncotype DX, Cancerguard, and Oncodetect tests. Abbott also offers consumer nutrition products including Ensure, Pedialyte, and Similac. The company sponsors the Abbott World Marathon Majors series and runs community programs like Abbott HeartMates. Abbott operates with approximately 122,000 employees and has been advancing life-changing healthcare technology since 1888.
Differentiator
Problem solved
Functional benefit
Brands
- FreeStyle Libre: Continuous glucose monitoring (CGM) systems for people with diabetes
- Lingo
- Ensure
- Similac
- Pedialyte
- HeartMate
- Exact Sciences
- Amplatzer
- CardioMEMS
- Aveir
- i-STAT
Products and services
- Venture Capital Investments in Emerging Medical Technology
Quantifiable outcome
- Abbott has increased dividends for 53 consecutive years, making it an attractive dividend stock for passive income investors
- +3 more outcomes
Companies that use Abbott Ventures
Customer profileNamed customers9 records
Segments6 records
Ideal customer profiles1 record
Abbott Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability4 records
Feature11 records
Abbott Ventures partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Exact SciencescoreAbbott acquired Exact Sciences in 2025, adding leading cancer testing products including Cologuard (colorectal cancer screening), Cancerguard (multi-cancer blood test), Oncotype DX (breast cancer recurrence test), and Oncodetect (circulating tumor DNA test) to Abbott's portfolio. The acquisition aims to advance earlier cancer detection and personalized treatment decisions for millions of people.
- Tedy BruschicoreThree-time NFL pro league champion Tedy Bruschi serves as ambassador for Abbott HeartMates. Bruschi experienced a stroke caused by a hole in his heart in 2005 and received an Abbott Amplatzer device, enabling him to rejoin his team months later and be named the 2005 Comeback Player of the Year.
- Damar HamlincoreNFL player Damar Hamlin serves as captain of the Abbott HeartMates program, a community for people with heart conditions and their loved ones to share stories and receive emotional support. Hamlin experienced a cardiac event during a game in January 2023 and made an inspiring comeback, embodying the program's message of resilience and community support.
- Real Madrid Football ClubcoreAbbott is the global health sciences and nutrition partner of Real Madrid FC since 2021. The partnership includes the Abbott-Real Madrid Innovation Lab inside Real Madrid's training facilities where Abbott scientists and Real Madrid's medical team work together to advance sports health, nutrition, and science. Real Madrid players use Abbott products like Ensure Max Protein and Pedialyte Sport.
- Real Madrid FoundationcoreAbbott is a global partner of the Real Madrid Foundation, working to combat global malnutrition through screening programs and nutrition education to help improve the well-being of children worldwide. The partnership delivered over 35,000 hours of nutrition education in 10 countries in 2023 and screened more than 1,700 students for malnutrition in six countries.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Abbott Ventures competitors and assessment
Company assessmentEmerging players
- Dexcom Ventures: Dexcom is a leading continuous glucose monitoring (CGM) company that competes with Abbott's FreeStyle Libre franchise and engages in adjacent strategic investments in metabolic health and diabetes technology. It is a relevant emerging peer given overlapping diabetes technology adjacency to Abbott Ventures' medical technology thesis.
Direct peers
- Philips Health Technology Ventures: Philips Health Technology Ventures is the corporate venture arm of Royal Philips, focused on medical devices, digital health, and diagnostics investments. It is a direct peer given comparable healthcare-major parent and similar medical technology and digital health investment focus.
- Novartis Venture Fund: Novartis Venture Fund is the corporate venture capital arm of Novartis, focused on early-stage life sciences, medical devices, and digital health investments. It is a direct peer given the comparable large-cap pharmaceutical/healthcare parent and similar sector-specialist CVC mandate.
- Johnson & Johnson Innovation (JJDC): Johnson & Johnson Innovation - JJDC is the dedicated corporate venture capital arm of Johnson & Johnson, making minority equity investments in early-stage healthcare and medical technology companies. It is the closest direct peer to Abbott Ventures given the comparable parent scale (large-cap healthcare major) and similar medical technology investment focus.
- Boston Scientific Ventures: Boston Scientific's corporate venture program targets minority investments in early-stage medical device companies, particularly in cardiology and structural heart adjacencies. It is a direct peer to Abbott Ventures given its medical device major parent and overlapping cardiovascular investment focus.
- Becton Dickinson (BD) Ventures: BD Ventures is the corporate venture arm of Becton Dickinson, investing in medical technology, diagnostics, and life sciences companies. It is a direct peer given comparable medical device/diagnostics-major parent and similar emerging medical technology investment thesis.
- Medtronic Ventures: Medtronic's corporate venture investing program targets emerging medical device, diagnostics, and digital health companies aligned with Medtronic's therapeutic areas. It is a direct peer to Abbott Ventures as both are medical-device-major CVCs with similar sector mandates and strategic-acquirer exit pathways.
- GE Healthcare Ventures: GE Healthcare has invested through various strategic venture initiatives targeting emerging medical imaging, diagnostics, and digital health companies. It is a direct peer to Abbott Ventures as a healthcare-major CVC with overlapping medical technology investment themes.
- Roche Venture Fund: Roche Venture Fund is the corporate venture arm of Roche, investing in early-stage diagnostics, medical devices, and digital health companies. It is a direct peer given comparable healthcare-major parent, similar sector focus, and equivalent strategic-investor value proposition to portfolio companies.
Broad incumbents
- Stryker (Corporate Development / Investments): Stryker is a major medical device incumbent that deploys strategic capital through M&A and minority investments in orthopedics, medical/surgical, and neurotechnology companies. It is comparable to Abbott Ventures as a medical-device-major strategic investor, though Stryker's strategic capital deployment is weighted toward larger M&A rather than early-stage venture.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Abbott Ventures social profiles
Digital presenceAbbott Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abbott Ventures leadership team
Management profileNumber of profiles
Profiles2 records
Abbott Ventures subsidiaries and ownership
Company hierarchySubsidiaries1 record
Abbott Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abbott Ventures M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abbott Ventures
What does Abbott Ventures do?
Abbott Ventures is a corporate venture capital subsidiary of Abbott that makes equity investments in emerging medical technology companies. It deploys strategic capital into early- and growth-stage medtech businesses, leveraging the parent organization's healthcare industry presence and product portfolio spanning medical devices, diagnostics, nutrition, and pharmaceuticals.
Is Abbott Ventures a public or private company?
Abbott Ventures is a public company. It is classified as corporate owned and is currently operating.
When was Abbott Ventures founded?
Abbott Ventures was founded in 1888. It employs 5,001 to 10,000 people.
Where is Abbott Ventures based?
Abbott Ventures is headquartered in Carthage, United States, in the North America region.
How does Abbott Ventures make money?
Five revenue lines are on record. Medical Devices are the primary driver. The others are diagnostics, nutrition, established Pharmaceuticals and cancer Testing (via Exact Sciences).
Who are Abbott Ventures's main competitors?
Dexcom Ventures is listed as an emerging player. Direct peers are Philips Health Technology Ventures, Novartis Venture Fund, Johnson & Johnson Innovation (JJDC), Boston Scientific Ventures, Becton Dickinson (BD) Ventures, Medtronic Ventures, GE Healthcare Ventures and Roche Venture Fund. Stryker (Corporate Development / Investments) is listed as a broad incumbent.
Does Abbott Ventures have an API?
No public API is recorded for Abbott Ventures.
What industry is Abbott Ventures in?
Abbott Ventures's product category is Venture Capital Investment. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52399 and its SIC code is 6282.